Merck & Co. Inc.

01/27/2022 | Press release | Distributed by Public on 01/27/2022 05:49

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery